The Himalaya Drug Company Introduces Quista DN

Bhubaneswar: The Himalaya Drug Company, one of India’s leading wellness brands, launches Quista DN, a nutritional supplement scientifically designed to effectively help in the dietary management of diabetic and prediabetic individuals. Quista DN is a sucrose free formula, fortified with unique ACCTI advantage nutrients (Alpha lipoic acid, Carnitine, Coenzyme Q10, Taurine, Inositol) that help improve overall metabolism. Quista DN is developed with the amalgamation of ancient wisdom of Ayurveda and modern nutrition science that contains botanical ingredients, ACCTI mix, Chromium, Zinc and Selenium, which collectively improve the blood glucose utilization in the body. This composition makes Quista DN ideal for in-between meals, which provides a feeling of satiation and helps counter unhealthy snacking.
“Quista DN is an extension of our ‘Quista’ range and is a unique formulation specifically for people with diabetes,” says Mr. Philipe Haydon, CEO, The Himalaya Drug Company. “Quista DN is a beneficial nutritional drink that Himalaya offers as an optimal solution to enable consumers with a validated formulation that enriches a diabetic’s diet,” says Mr. Anil Jiandani, Business Director, Pharmaceutical Division, The Himalaya Drug Company.
Quista DN is fortified with botanical ingredients like Apple (Seva) and Banaba (Jarula) extract, which are known to help reduce intestinal glucose absorption and insulin resistance, thereby promoting glucose uptake by muscle cells. With ‘Sustained Energy Release’ carbohydrates in the combination of isomaltulose, fructose, and lactose, the formula is a low Glycemic Index (GI) product. It is a vegetarian product that contains slow and medium digesting proteins, soluble and insoluble fiber, which additionally help in an optimize glycemic response. Quista DN is available in 400gm packs at all leading chemist outlets and online stores and is priced at 550/- for consumers across India. It comes in two delicious flavors – Vanilla and Milk Masala.

Comments are closed.